New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
19:08 EDTCODE, SNY, MANH, AMZN, WBSN, ISIS, UIS, KERX, BRCM, CHK, DLBOn The Fly: After Hours Movers
UP AFTER EARNINGS: Amazon (AMZN), up 9.2%... Dolby (DLB), up 4.2%... Unisys (UIS), up 10.9%... Manhattan Associates (MANH), up 3.6%... ALSO HIGHER: Chesapeake Energy (CHK), up 9.4% after CEO Aubrey McClendon announced he would retire April 1... ISIS Pharmaceuticals (ISIS), up 7.6% after the company announced it will receive a $25M milestone payment from Sanofi (SNY) following FDA approval of Kynamro... DOWN AFTER EARNINGS: Broadcom (BRCM), down 0.6%... Websense (WBSN), down 3.6%... Spansion (CODE), down 8.9%... ALSO LOWER: Keryx (KERX), down 2.7% after commencing the offering of $55M of common stock.
News For AMZN;DLB;UIS;MANH;CHK;ISIS;SNY;BRCM;WBSN;CODE;KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 15, 2015
17:33 EDTBRCMPoint72 Asset Management gives quarterly update on stakes
Subscribe for More Information
16:35 EDTCHKIcahn Associates gives quarterly update on stakes
NEW STAKES: None. INCREASED STAKES: Manitowoc (MTW), Voltari (VLTC), Federal-Mogul Holdings (FDML), and Chesapeake Energy (CHK). DECREASED STAKES: None. LIQUIDATED STAKES: None.
16:01 EDTAMZNOptions Update; May 15, 2015
iPath S&P 500 VIX Short-Term Futures down 20c to 20.06 Option volume leaders: AAPL BAC FB NFLX TWTR BABA CSCO TSLA MU GILD T MSFT AMZN MCD
10:45 EDTCHKStocks with call strike movement; CHK RIG
Chesapeake (CHK) October 17 call option implied volatility increased 2% to 45, Transocean (RIG) August 21 call option implied volatility increased 4% to 42 according to IVolatility.
10:29 EDTSNYAmerican Urological Association to hold an annual meeting
Subscribe for More Information
May 14, 2015
18:55 EDTAMZNAmazon in talks to expand Prime product selection, Re/code says
Amazon is in talks with select merchants to include products in the Prime two-day shipping program without requiring them to be stored in Amazon warehouses, reports Re/code, citing multiple people familiar with the program. The report notes that Amazon previously required that all Prime products be stored in the company's own warehouses, indicating that the move is a concession to sellers in exchange for improving the Prime experience. Reference Link
13:28 EDTCHKIncreasing equity options volume
Increasing equity options volume: FCX UPS KSS CHK CSCO AVP YOKU CALM KORS
09:06 EDTBRCMSynopsys and Broadcom extend license agreement
Subscribe for More Information
07:48 EDTBRCMBroadcom management to meet with Deutsche Bank
Meeting to be held in Los Angeles on May 14 hosted by Deutsche Bank.
05:49 EDTBRCMStocks with implied volatility movement; ESI BRCM
Subscribe for More Information
May 13, 2015
18:09 EDTAMZNWal-Mart to launch $50 unlimited shipping service in summer, AP says
Subscribe for More Information
14:52 EDTAMZNAmazon launches new mobile advertising platform
Amazon has launched a new advertising platform for mobile app developers that promises to "promote your app to millions of users on Fire tablet wakescreens and mobile placements on the Amazon Mobile Ad Network." Amazon automatically generates advertisements once an ad placement order is submitted, and touts that an ad campaign can be launched in as little as 90 seconds. Reference Link
13:28 EDTAMZNWal-Mart set to launch Amazon Prime rival, The Information reports
Wal-Mart (WMT) is nearing the launch of a subscription fast-shipping service that will compete with Amazon Prime (AMZN), Amir Efrati of The Information reports, citing people involved with or briefed on the product. The service is an attempt to boost Wal-Mart's online business and should launch in the next few weeks after being pushed back for technical and other issues, Efrati adds. Shares of Amazon are down $2.63 to $428.39 in afternoon trading while Wal-Mart is down 66c to $78.30. Reference Link
13:23 EDTAMZNWal-Mart set to launch rival to Amazon Prime, The Information reports
Subscribe for More Information
11:28 EDTCHKStocks with call strike movement; TWTR JCP
Subscribe for More Information
09:56 EDTBRCMEquity options with increasing volume
Subscribe for More Information
09:39 EDTAMZNActive equity options trading on open
Subscribe for More Information
09:04 EDTAMZNHouse Judiciary Committee to hold a hearing
The Subcommittee on Courts, Intellectual Property and the Internet holds a hearing entitled, "Stakeholder Perspectives on ICANN: The .Sucks Domain and Essential Steps to Guarantee Trust and Accountability in the Internets Operation" with Vice President Misener of Amazon.com on May 13 at 10 am. Webcast Link
07:31 EDTSNYHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:05 EDTSNYSanofi exercises option on therapeutic program with Selecta Biosciences
Selecta Biosciences., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi. November 2012, Selecta announced that they had formed a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life threatening allergies. Under the agreement, Sanofi obtained a first exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies and celiac disease. With the exercise of this option by Sanofi, Selecta and Sanofi now have two initiatives actively advancing immune tolerance treatments under the terms of the 2012 agreement. In October 2014, Selecta and JDRF announced another collaboration with Sanofi to research novel antigen-specific immune therapies for Type 1 Diabetes.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use